Ocugen to Host Conference Call on Friday, August 6 at 8:30 a.m. ET to Discuss Second Quarter 2021 Financial Results and Provide Business Update
July 30 2021 - 8:45AM
Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on
discovering, developing, and commercializing gene therapies to cure
blindness diseases and developing a vaccine to save lives from
COVID-19, today announced that it will host a conference call to
discuss its second quarter 2021 financial results and provide a
business update at 8:30 a.m. ET on Friday, August 6, 2021.
Ocugen will issue a pre-market earnings announcement on the same
day. Investors are invited to participate on the call using the
following details:
- Dial-In Number: (844) 873-7330 (U.S.) or (602) 563-8473
(international)
- Conference ID: 6663619
- Webcast: Available in the “Investors” section of the Ocugen
website and archived for approximately 45 days following the
call
About Ocugen, Inc.Ocugen, Inc. is a
biopharmaceutical company focused on discovering, developing, and
commercializing gene therapies to cure blindness diseases and
developing a vaccine to save lives from COVID-19. Our breakthrough
modifier gene therapy platform has the potential to
treat multiple retinal diseases with one drug – “one to many”
and our novel biologic product candidate aims to offer better
therapy to patients with underserved diseases such as wet
age-related macular degeneration, diabetic macular edema, and
diabetic retinopathy. We are co-developing Bharat Biotech’s
COVAXIN™ vaccine candidate for COVID-19 in the U.S. and
Canadian markets. For more information, please
visit www.ocugen.com.Cautionary Note on
Forward-Looking Statements This press release contains
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995, which are subject to
risks and uncertainties. Such forward-looking statements within
this press release include, without limitation, the intended use of
net proceeds from the registered direct offering. We may, in some
cases, use terms such as “predicts,” “believes,” “potential,”
“proposed,” “continue,” “estimates,” “anticipates,” “expects,”
“plans,” “intends,” “may,” “could,” “might,” “will,” “should” or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. Such statements are
subject to numerous important factors, risks and uncertainties that
may cause actual events or results to differ materially from our
current expectations, such as market and other conditions. These
and other risks and uncertainties are more fully described in our
periodic filings with the Securities and Exchange Commission (the
“SEC”), including the risk factors described in the section
entitled “Risk Factors” in the quarterly and annual reports that we
file with the SEC. Any forward-looking statements that we make in
this press release speak only as of the date of this press release.
Except as required by law, we assume no obligation to update
forward-looking statements contained in this press release whether
as a result of new information, future events or otherwise, after
the date of this press release.
Ocugen Contact: Ken InchaustiHead,
Investor Relations & CommunicationsIR@Ocugen.com
Please submit investor-related inquiries
to: IR@ocugen.com
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Apr 2023 to Apr 2024